Cardiac resynchronization was effective for moderate-to
... The MIRACLE trial shows that 1 in 5 patients with advanced symptomatic congestive heart failure and an intraventricular conduction delay have incremental improvement of ≥ 1 NYHA symptom class at 6 months with biventricular pacing. Limited information is available at present to predict the subset of ...
... The MIRACLE trial shows that 1 in 5 patients with advanced symptomatic congestive heart failure and an intraventricular conduction delay have incremental improvement of ≥ 1 NYHA symptom class at 6 months with biventricular pacing. Limited information is available at present to predict the subset of ...
Slide 1 - AccessCardiology
... Postoperative automatic junctional tachycardia 8 hours after complete repair of AV septal defect in a 3-month-old infant. Using the V1−V2−V3 montage from a standard electrocardiographic recording device, the device cables corresponding to V1 and V2 are connected to the two temporary atrial epicardia ...
... Postoperative automatic junctional tachycardia 8 hours after complete repair of AV septal defect in a 3-month-old infant. Using the V1−V2−V3 montage from a standard electrocardiographic recording device, the device cables corresponding to V1 and V2 are connected to the two temporary atrial epicardia ...
Anaesthesia for patients with grown up congenital heart disease
... increase. • Ideal facilities and care pathways are yet to materialise • When confronted; – Back to basics – Make a good plan – Discuss with other colleagues (centre if possible) ...
... increase. • Ideal facilities and care pathways are yet to materialise • When confronted; – Back to basics – Make a good plan – Discuss with other colleagues (centre if possible) ...
Summary implantable cardiac defibrillator (ICD)
... defibrillator (ICD) in cases of heart failure. An ICD is an active implant that supplies the heart with a defibrillating high energy shock when a ventricular fibrillation is detected. The implant can also emit a weaker electrical stimulation in order to prevent a dysrhythmia becoming a ventricular f ...
... defibrillator (ICD) in cases of heart failure. An ICD is an active implant that supplies the heart with a defibrillating high energy shock when a ventricular fibrillation is detected. The implant can also emit a weaker electrical stimulation in order to prevent a dysrhythmia becoming a ventricular f ...
MP3-15 Familial WPW and hypertrophic cardiomyopathy caused by
... Results Of 8 patients, 7 had PRKAG2 mutations, R302Q or R344P. Six patients underwent cardiac MRI. Two symptomatic R302Q patients with palpitations and decreased exercise capacity had significantly elevated left ventricular (LV) mass in a symmetric pattern (picture 1). Midventricular myocardium was ...
... Results Of 8 patients, 7 had PRKAG2 mutations, R302Q or R344P. Six patients underwent cardiac MRI. Two symptomatic R302Q patients with palpitations and decreased exercise capacity had significantly elevated left ventricular (LV) mass in a symmetric pattern (picture 1). Midventricular myocardium was ...
job description
... The post-holder will be trained to perform right heart catheterisation, endomyocardial biopsy and intra-aortic balloon pump insertion. They will become experienced in the assessment of critically ill patients with heart failure, the basic management of immunotherapy and associated complications, the ...
... The post-holder will be trained to perform right heart catheterisation, endomyocardial biopsy and intra-aortic balloon pump insertion. They will become experienced in the assessment of critically ill patients with heart failure, the basic management of immunotherapy and associated complications, the ...
Hypertrophic Cardiomyopathy
... Jennifer Terker Professor of Pediatrics Division Chief, Pediatric Cardiology Medical Director, Heart Transplant Program The Children’s Hospital of Philadelphia University of Pennsylvania School of Medicine ...
... Jennifer Terker Professor of Pediatrics Division Chief, Pediatric Cardiology Medical Director, Heart Transplant Program The Children’s Hospital of Philadelphia University of Pennsylvania School of Medicine ...
CTR 210 - Heart Failure Society of America
... All patients with a reduced LVEF may not benefit from an implantable cardiac defibrilator (ICD)1,2: • About one-third of the total study population in MADIT II was classified as “lowrisk” and had a 2-year mortality of only 8%, receiving no benefit from an ICD3. • Patients with an LVEF between 30-35% ...
... All patients with a reduced LVEF may not benefit from an implantable cardiac defibrilator (ICD)1,2: • About one-third of the total study population in MADIT II was classified as “lowrisk” and had a 2-year mortality of only 8%, receiving no benefit from an ICD3. • Patients with an LVEF between 30-35% ...
for immediate release - Miami`s Community Newspapers
... Dr. Jacobson is an expert in the diagnosis and treatment of heart rhythm disorders, such as atrial fibrillation, ventricular tachycardia in structural heart disease, supraventricular tachycardia, and other forms of arrhythmia. He also is skilled at cardiac catheter ablation, a minimally invasive tec ...
... Dr. Jacobson is an expert in the diagnosis and treatment of heart rhythm disorders, such as atrial fibrillation, ventricular tachycardia in structural heart disease, supraventricular tachycardia, and other forms of arrhythmia. He also is skilled at cardiac catheter ablation, a minimally invasive tec ...
Skipping the Beat The “Beatless” Heart
... why must a substitute heart beat like a natural one? ‘Mother nature did the best she could’” ~Billy Cohn, researcher at Texas Heart Institute ...
... why must a substitute heart beat like a natural one? ‘Mother nature did the best she could’” ~Billy Cohn, researcher at Texas Heart Institute ...
Ventricular Late potentials
... of repolariztion of ventricular myocytes. T wave alternans testing requires exercise or atrial pacing to achieve a heart rate of 100 to 120 beats/min with relatively little atrial or ventricular ectopic activity The test is less useful in patients with wide QRS complex(longer than 120 milliseconds). ...
... of repolariztion of ventricular myocytes. T wave alternans testing requires exercise or atrial pacing to achieve a heart rate of 100 to 120 beats/min with relatively little atrial or ventricular ectopic activity The test is less useful in patients with wide QRS complex(longer than 120 milliseconds). ...
is minimally invasive left ventricular epicardial lead implantation the
... LV epicardial lead placement using minimally invasive surgical approaches. Methods: From 10/02 through 10/08, 205 patients underwent minimally invasive LV lead placement .This includes, 65 (32%) video-assisted thoracoscopic, and 140 (68%) mini-thoracotomy surgeries. One hundred forty-five (70%) were ...
... LV epicardial lead placement using minimally invasive surgical approaches. Methods: From 10/02 through 10/08, 205 patients underwent minimally invasive LV lead placement .This includes, 65 (32%) video-assisted thoracoscopic, and 140 (68%) mini-thoracotomy surgeries. One hundred forty-five (70%) were ...
Notes on CHF
... 7. Beta-adrenergic antagonists can dramatically reduce hospitalizations and increase the survival of patients with heart failure. Although beta-blockers decrease myocardial contractility, they also lower heart rate and blood pressure, which are beneficial to reducing the symptoms of HF. When admini ...
... 7. Beta-adrenergic antagonists can dramatically reduce hospitalizations and increase the survival of patients with heart failure. Although beta-blockers decrease myocardial contractility, they also lower heart rate and blood pressure, which are beneficial to reducing the symptoms of HF. When admini ...
Morte cardiaca improvvisa - Informazioni
... Sudden cardiac arrest (SCA) and the role of transvenous defibrillators (ICD) and sub-cutaneous defibrillators (S-ICD) What Is Sudden Cardiac Arrest? Sudden cardiac arrest (SCA) is a life-threating heart condition, and if not treated within minutes, can lead to death. SCA results from an irregular or ...
... Sudden cardiac arrest (SCA) and the role of transvenous defibrillators (ICD) and sub-cutaneous defibrillators (S-ICD) What Is Sudden Cardiac Arrest? Sudden cardiac arrest (SCA) is a life-threating heart condition, and if not treated within minutes, can lead to death. SCA results from an irregular or ...
Plötzlicher Herztod - Hintergrundinformationen
... Sudden cardiac arrest (SCA) and the role of transvenous defibrillators (ICD) and sub-cutaneous defibrillators (S-ICD) What Is Sudden Cardiac Arrest? Sudden cardiac arrest (SCA) is a life-threating heart condition, and if not treated within minutes, can lead to death. SCA results from an irregular or ...
... Sudden cardiac arrest (SCA) and the role of transvenous defibrillators (ICD) and sub-cutaneous defibrillators (S-ICD) What Is Sudden Cardiac Arrest? Sudden cardiac arrest (SCA) is a life-threating heart condition, and if not treated within minutes, can lead to death. SCA results from an irregular or ...
- Via Medica Journals
... Six years after CB-MNC therapy, the parameters such as NT-pro-BNP, 6-min walking test, and left ventricular ejection fraction were relatively stable. This case indicated that an intravenous injection of CB-MNCs can significantly improve left ventricular performance, quality of life, and mortality of ...
... Six years after CB-MNC therapy, the parameters such as NT-pro-BNP, 6-min walking test, and left ventricular ejection fraction were relatively stable. This case indicated that an intravenous injection of CB-MNCs can significantly improve left ventricular performance, quality of life, and mortality of ...
Electric Currents Applied During the Refractory Period Can
... occlusion. The ESPVR is determined by connecting the upper left corner of the pressure-volume loop of each beat during the series. The upward shift of the ESPVR during CCM application demonstrates that regional function can be suf®ciently in¯uenced to have a signi®cant impact on global function. The ...
... occlusion. The ESPVR is determined by connecting the upper left corner of the pressure-volume loop of each beat during the series. The upward shift of the ESPVR during CCM application demonstrates that regional function can be suf®ciently in¯uenced to have a signi®cant impact on global function. The ...
4 Abstract from Tina..
... echocardiography was done before and after treatment. Cardiac function, myocardial substrate utilization and oxygen consumption was measured in isolated perfused hearts. Results. AngII treatment led to a slight reduction in body weight gain, while there was no measurable effect on blood pressure. Ec ...
... echocardiography was done before and after treatment. Cardiac function, myocardial substrate utilization and oxygen consumption was measured in isolated perfused hearts. Results. AngII treatment led to a slight reduction in body weight gain, while there was no measurable effect on blood pressure. Ec ...
resynchronisation therapy in adults with congenital heart disease
... Adult Congenital Cardiac Unit, Southampton University Hospital, Southampton, Hampshire, UK Objectives:Cardiac resynchronization therapy (CRT) may be of particular benefit to adults with congenital heart disease (CHD) and ventricular dysfunction (VD). Methods : Retrospective hospital records review.R ...
... Adult Congenital Cardiac Unit, Southampton University Hospital, Southampton, Hampshire, UK Objectives:Cardiac resynchronization therapy (CRT) may be of particular benefit to adults with congenital heart disease (CHD) and ventricular dysfunction (VD). Methods : Retrospective hospital records review.R ...
Pre-Lecture Quiz
... 5. Blood flow that has been lost as a result of myocardial infarction cannot be reestablished. ...
... 5. Blood flow that has been lost as a result of myocardial infarction cannot be reestablished. ...
Study protocol NOAC
... improved pediatric care, childhood mortality has become uncommon and survival to adulthood is now expected. As a consequence, a rapidly increasing cohort of adult survivors has evolved. However, these adults are not cured. Many are at high risk of premature cardiac death as young adults. Their risk ...
... improved pediatric care, childhood mortality has become uncommon and survival to adulthood is now expected. As a consequence, a rapidly increasing cohort of adult survivors has evolved. However, these adults are not cured. Many are at high risk of premature cardiac death as young adults. Their risk ...
Public Summary Document
... MSAC considered the clinical effectiveness to be uncertain. Data showed that CCM improved symptoms, quality of life and exercise parameters of up to 12 months; however the durability of this benefit beyond 12 months is unknown. MSAC noted the uncertain effect on mortality and hospitalisation. MSAC f ...
... MSAC considered the clinical effectiveness to be uncertain. Data showed that CCM improved symptoms, quality of life and exercise parameters of up to 12 months; however the durability of this benefit beyond 12 months is unknown. MSAC noted the uncertain effect on mortality and hospitalisation. MSAC f ...
S-ICD® System - Factsheet
... o Annual inappropriate shock rate of 7 percent with some of these patients receiving shocks due to the rate of the arrhythmia being so high that shock therapy is applied without discrimination. Additional data coming from the EFFORTLESS registry will be presented at the EHRA EUROPACE 2013 congress. ...
... o Annual inappropriate shock rate of 7 percent with some of these patients receiving shocks due to the rate of the arrhythmia being so high that shock therapy is applied without discrimination. Additional data coming from the EFFORTLESS registry will be presented at the EHRA EUROPACE 2013 congress. ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.